Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 6/2019

01-06-2019 | Osteoporosis | Original Article

Use of antiosteoporotic medication in the Danish ROSE population-based screening study

Authors: M. P. Høiberg, K. H. Rubin, T. Holmberg, M. J. Rothmann, S. Möller, J. Gram, M. Bech, K. Brixen, A. P. Hermann

Published in: Osteoporosis International | Issue 6/2019

Login to get access

Abstract

Summary

Use of antiosteoporotic medication in the population-based, risk-stratified osteoporosis strategy evaluation (ROSE) screening study, comparing the use of FRAX followed by DXA with usual care, was examined. Screening increased the overall use of medication. Being recommended treatment by the hospital and higher age increased the likelihood of starting medication, but, nevertheless, a large percentage opted not to start treatment.

Introduction

The aim of the study was to examine the impact on medication prescription, adherence, and persistence of osteoporotic medicine in the randomized population-based ROSE screening study for osteoporosis.

Methods

The Danish ROSE study included a population-based random sample of women aged 65–81 years randomized to either a two-step screening program consisting of FRAX followed by DXA for high-risk participants or opportunistic screening for osteoporosis (usual care). This sub-study on the intention-to-treat population examined the impact of the screening program on antiosteoporotic medication redemption rates, adherence, and persistence using Danish registers.

Results

A total of 30,719 of 34,229 women were treatment-naïve. Significantly more participants in the screening group started on antiosteoporotic medication, but no differences in adherence and persistence rates were found. Higher age was associated with a higher likelihood of starting medication. A low Charlson comorbidity score (= 1) was associated with higher treatment initiation but lower adherence and persistence of antiosteoporotic treatment. A total of 31.7% of participants advised to initiate treatment did not follow the advice.

Conclusions

Screening for osteoporosis using FRAX followed by DXA increased the overall use of antiosteoporotic medication in the screening group without differences in adherence and persistence rates. A large percentage of participants advised to initiate treatment did nevertheless fail to do so.
Appendix
Available only for authorised users
Literature
1.
Kanis JA, Borgstrom F, Compston J, Dreinhofer K, Nolte E, Jonsson L, Lems WF, McCloskey EV, Rizzoli R, Stenmark J (2013) SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos 8:144CrossRefPubMedPubMedCentral
2.
Rubin KH, Abrahamsen B, Hermann AP, Bech M, Gram J, Brixen K (2011) Prevalence of risk factors for fractures and use of DXA scanning in Danish women. A regional population-based study. Osteoporos Int : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 22:1401–1409CrossRef
3.
Hoiberg MP, Rubin KH, Gram J, Hermann AP, Brixen K, Haugeberg G (2015) Risk factors for osteoporosis and factors related to the use of DXA in Norway. Arch Osteoporos 10:16CrossRefPubMed
4.
Johansson H, Kanis JA, Oden A, Johnell O, McCloskey E (2009) BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20:1675–1682CrossRef
5.
Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, Jonsson B, Pols H, Cramer JA (2007) Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 18:711–719CrossRef
6.
7.
Organisation WHO (2003) Adherence to long-term therapies. Evidence for action. In E S (ed)
8.
Cadarette SM, Solomon DH, Katz JN, Patrick AR, Brookhart MA (2011) Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporos Int : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 22:943–954CrossRef
9.
Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022CrossRefPubMed
10.
Olsen KR, Hansen C, Abrahamsen B (2013) Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases. Osteoporos Int : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 24:2639–2647CrossRef
11.
Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493–1501CrossRefPubMed
12.
Rubin KH, Holmberg T, Rothmann MJ, Høiberg M, Barkmann R, Gram J, Hermann AP, Bech M, Rasmussen O, Glüer CC, Brixen K (2015) The risk-stratified osteoporosis strategy evaluation study (ROSE): a randomized prospective population-based study. Design and baseline characteristics. Calcif Tissue Int 96:167–179CrossRefPubMed
13.
von Saltman RB, Vrangbaek, K. (2006) Primary care in the driver's seat? Open University Press,
14.
Rubin KH, Rothmann MJ, Holmberg T, Høiberg M, Möller S, Barkmann R, Glüer CC, Hermann AP, Bech M, Gram J, Brixen K (2018) Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized risk-stratified osteoporosis strategy evaluation (ROSE) study. Osteoporos Int : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 29:567–578CrossRef
15.
16.
Rubin KH, Abrahamsen B, Hermann AP, Bech M, Gram J, Brixen K (2011) Fracture risk assessed by fracture risk assessment tool (FRAX) compared with fracture risk derived from population fracture rates. Scand J Public Health 39:312–318CrossRefPubMed
17.
Rubin KH, Rothmann MJ, Holmberg T et al (2017) Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized risk-stratified osteoporosis strategy evaluation (ROSE) study. Osteoporos Int : a journal established as result of cooperation between the European Foundation for osteoporosis and the National Osteoporosis Foundation of the USA 29(3):567–578CrossRef
18.
Thygesen LC, Ersboll AK (2011) Danish population-based registers for public health and health-related welfare research: introduction to the supplement. Scand J Public Health 39:8–10CrossRefPubMed
19.
Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT (2015) The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449–490CrossRefPubMedPubMedCentral
20.
Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, Sorensen HT, Hallas J, Schmidt M (2017) Data resource profile: the Danish National Prescription Registry. Int J Epidemiol 46:798–798fPubMed
21.
Methodology WCCfDS (2014) Guidelines for ATC classification and DDD assignment, 2015
22.
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed
23.
Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value in Health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 11:44–47CrossRef
24.
Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M (2007) A checklist for medication compliance and persistence studies using retrospective databases. Value in Health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 10:3–12CrossRef
25.
26.
27.
Schmidt M, Pedersen L, Sorensen HT (2014) The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol 29:541–549CrossRefPubMed
28.
Baadsgaard M, Quitzau J (2011) Danish registers on personal income and transfer payments. Scand J Public Health 39:103–105CrossRefPubMed
29.
30.
Weaver J, Sajjan S, Lewiecki EM, Harris ST (2017) Diagnosis and treatment of osteoporosis before and after fracture: a side-by-side analysis of commercially insured and Medicare advantage osteoporosis patients. J Manag Care Special Pharm 23:735–744CrossRef
31.
Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 17:914–921CrossRef
32.
Kyvernitakis I, Kostev K, Kurth A, Albert US, Hadji P (2014) Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider. Osteoporos Int : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 25:2721–2728CrossRef
33.
Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Strom O (2015) Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 26:2401–2411CrossRef
34.
Kjellberg J, Jorgensen AD, Vestergaard P, Ibsen R, Gerstoft F, Modi A (2016) Cost and health care resource use associated with noncompliance with oral bisphosphonate therapy: an analysis using Danish health registries. Osteoporos Int : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 27:3535–3541CrossRef
35.
Hansen L, Petersen KD, Eriksen SA, Gerstoft F, Vestergaard P (2017) Subjects with osteoporosis to remain at high risk for fracture despite benefit of prior bisphosphonate treatment-a Danish case-control study. Osteoporos Int : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 28:321–328CrossRef
36.
Thorsteinsson AL, Vestergaard P, Eiken P (2015) Compliance and persistence with treatment with parathyroid hormone for osteoporosis. A Danish national register-based cohort study. Arch Osteoporos 10:35CrossRefPubMed
37.
Briot K, Ravaud P, Dargent-Molina P, Zylberman M, Liu-Leage S, Roux C (2009) Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20:625–630CrossRef
38.
Hadji P, Jacob L, Kostev K (2016) Gender- and age-related treatment compliance in patients with osteoporosis in Germany. Patient Prefer Adherence 10:2379–2385CrossRefPubMedPubMedCentral
39.
Laius O, Pisarev H, Maasalu K, Koks S, Martson A (2017) Adherence to osteoporosis medicines in Estonia-a comprehensive 15-year retrospective prescriptions database study. Arch Osteoporos 12:59CrossRefPubMed
40.
Reynolds K, Muntner P, Cheetham TC, Harrison TN, Morisky DE, Silverman S, Gold DT, Vansomphone SS, Wei R, O'Malley CD (2013) Primary non-adherence to bisphosphonates in an integrated healthcare setting. Osteoporos Int : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 24:2509–2517CrossRef
41.
Hurtado I, Sanfelix-Gimeno G, Peiro S, Sanfelix-Genoves J (2015) Primary non-adherence to antiosteoporotic treatment and associated factors: a prospective cohort study in Spain. Value in Health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 18:A650CrossRef
42.
Garcia-Sempere A, Hurtado I, Sanfelix-Genoves J, Rodriguez-Bernal CL, Gil Orozco R, Peiro S, Sanfelix-Gimeno G (2017) Primary and secondary non-adherence to osteoporotic medications after hip fracture in Spain. The PREV2FO population-based retrospective cohort study. Sci Rep 7:11784CrossRefPubMedPubMedCentral
43.
Kalluru R, Petrie KJ, Grey A, Nisa Z, Horne AM, Gamble GD, Bolland MJ (2017) Randomised trial assessing the impact of framing of fracture risk and osteoporosis treatment benefits in patients undergoing bone densitometry. BMJ Open 7:e013703CrossRefPubMedPubMedCentral
44.
Rothmann MJ, Ammentorp J, Bech M, Gram J, Rasmussen OW, Barkmann R, Gluer CC, Hermann AP (2015) Self-perceived facture risk: factors underlying women's perception of risk for osteoporotic fractures: the risk-stratified osteoporosis strategy evaluation study (ROSE). Osteoporos Int : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 26:689–697CrossRef
Metadata
Title
Use of antiosteoporotic medication in the Danish ROSE population-based screening study
Authors
M. P. Høiberg
K. H. Rubin
T. Holmberg
M. J. Rothmann
S. Möller
J. Gram
M. Bech
K. Brixen
A. P. Hermann
Publication date
01-06-2019
Publisher
Springer London
Published in
Osteoporosis International / Issue 6/2019
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-019-04934-7

Other articles of this Issue 6/2019

Osteoporosis International 6/2019 Go to the issue

Original Article

Opportunistic osteoporosis screening in multi-detector CT images via local classification of textures

Original Article

Extensive undertreatment of osteoporosis in older Swedish women

Original Article

Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis

Review Article

Metformin use and risk of fracture: a systematic review and meta-analysis of observational studies

Original Article

Texture analysis of vertebral bone marrow using chemical shift encoding–based water-fat MRI: a feasibility study

Letter to the Editor

Visit-to-visit blood pressure variability and hip fracture: response to comments by Nagai et al.